Cytarabine

Generic Name: Cytarabine

Brand Names: Cytosar, Vyxeos

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₃N_₃O_₅

CAS Number: 147-94-4

Unique Ingredient Identifier: 04079A1RDZ

Background: A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

Indication: For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.

Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

Associated Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia

Clinical Trials

Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: rituximab
Drug: cisplatin
Drug: cytarabine
Drug: dexamethasone
Drug: sargramostim

First Posted Date: 2003-01-27

Last Posted Date: 2016-12-07

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 58

Registration Number: NCT00005601

Locations: 🇺🇸
CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States
🇺🇸
CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States
🇺🇸
CCOP - Cedar Rapids Oncology Project, Cedar Rapids, Iowa, United States

and more 18 locations

Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma

Phase 3

Completed

Conditions: Leukemia
Lymphoma

Interventions: Biological: dactinomycin
Biological: sargramostim
Drug: carmustine
Drug: cyclophosphamide
Drug: cytarabine
Drug: daunorubicin hydrochloride
Drug: doxorubicin hydrochloride
Drug: methotrexate
Drug: etoposide
Drug: mercaptopurine
Drug: prednisone
Drug: mitoxantrone hydrochloride
Drug: pegaspargase
Drug: vincristine sulfate
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2016-02-22

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 170

Registration Number: NCT00002766

Locations: 🇺🇸
Stanford Cancer Center at Stanford University Medical Center, Stanford, California, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States

and more 4 locations

Combination Chemotherapy in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia

Phase 2

Completed

Conditions: Leukemia
Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-12-19

Lead Sponsor: Medical Research Council

Target Recruit Count: 120

Registration Number: NCT00040690

Locations: 🇬🇧
Medical Research Council Clinical Trials Unit, London, England, United Kingdom

Combination Chemotherapy and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia

Phase 2

Completed

Conditions: Leukemia

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-25

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 30

Registration Number: NCT00002598

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Combination Chemotherapy, Bone Marrow or Peripheral Stem Cell Transplantation, and/or Biological Therapy in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2012-06-06

Lead Sponsor: Northwestern University

Registration Number: NCT00004231

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States

Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase 3

Completed

Conditions: Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms
Leukemia

First Posted Date: 2003-01-27

Last Posted Date: 2013-12-18

Lead Sponsor: Leukemia Research Fund

Target Recruit Count: 2000

Registration Number: NCT00005823

Locations: 🇬🇧
University Hospital of Wales, Cardiff, Wales, United Kingdom
🇬🇧
University College Hospital, London, England, United Kingdom
🇬🇧
Queen Elizabeth Hospital at University of Birmingham, Birmingham, England, United Kingdom

S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: filgrastim
Biological: rituximab
Drug: cyclophosphamide
Drug: cytarabine
Drug: dexamethasone
Drug: doxorubicin
Drug: leucovorin
Drug: methotrexate
Drug: vincristine

First Posted Date: 2003-01-27

Last Posted Date: 2012-11-01

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 56

Registration Number: NCT00041132

Chemotherapy and Peripheral Stem Cell Transplant With or Without Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Phase 3

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-08-12

Lead Sponsor: Commissie Voor Klinisch Toegepast Onderzoek

Target Recruit Count: 340

Registration Number: NCT00012051

Locations: 🇳🇱
Academisch Medisch Centrum at University of Amsterdam, Amsterdam, Netherlands
🇧🇪
U.Z. Gasthuisberg, Leuven, Belgium
🇳🇱
HagaZiekenhuis - Locatie Leyenburg, 's-Gravenhage, Netherlands

and more 14 locations

Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase 3

Completed

Conditions: Leukemia
Myelodysplastic Syndromes

First Posted Date: 2003-01-27

Last Posted Date: 2010-06-22

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Registration Number: NCT00002517

Locations: 🇫🇷
Centre Hospitalier Regional et Universitaire d'Angers, Angers, France
🇧🇪
Algemeen Ziekenhuis Middelheim, Antwerp, Belgium
🇧🇪
Hopital Universitaire Des Enfants Reine Fabiola, Brussels, Belgium

and more 20 locations

Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia or Lymphoma

Phase 2

Completed

Conditions: Leukemia
Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2010-06-11

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 3

Registration Number: NCT00047021

Locations: 🇺🇸
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy